Octreotide uptake in parathyroid adenoma.
Identifieur interne : 000B69 ( Main/Exploration ); précédent : 000B68; suivant : 000B70Octreotide uptake in parathyroid adenoma.
Auteurs : RBID : pubmed:23487397Abstract
The patient with a history of bone pain and muscle weakness, was thought to have oncogenic osteomalacia as a result of biochemical investigations and directed to Nuclear Medicine Department for a whole-body bone scintigraphy and 111In-octreotide scintigraphy. There was no focal pathologic tracer uptake, but generalized marked increase in skeletal uptake on bone scintigraphy. Octreotide scintigraphy showed accumulation of octreotide in the region of the left lobe of the thyroid gland in the neck. Thereafter, parathyroid scintigraphy was performed with technetium-99m labeled metroxy-isobutyl-isonitryl (99mTc-MIB) and MIBI scan demonstrated radiotracer uptake at the same location with octreotide scintigraphy. The patient underwent left inferior parathyroidectomy and histopathology confirmed a parathyroid adenoma. Somatostatin receptor positive parathyroid adenoma may show octreotide uptake. Octreotide scintigraphy may be promising and indicate a possibility of using somatostatin analogues for the medical treatment of somatostatin receptor positive Conflict of interest:None declared.
DOI: 10.4274/Mirt.4
PubMed: 23487397
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Octreotide uptake in parathyroid adenoma.</title><author><name sortKey="Karacavu, Seyhan" uniqKey="Karacavu S">Seyhan Karaçavuş</name><affiliation wicri:level="1"><nlm:affiliation>Bozok University School of Medicine, Nuclear Medicine Department of, Yozgat, Turkey.</nlm:affiliation><country xml:lang="fr">Turquie</country><wicri:regionArea>Bozok University School of Medicine, Nuclear Medicine Department of, Yozgat</wicri:regionArea></affiliation></author><author><name sortKey="Kula, Mustafa" uniqKey="Kula M">Mustafa Kula</name></author><author><name sortKey="Cihan Karaca, Z Leyha" uniqKey="Cihan Karaca Z">Züleyha Cihan Karaca</name></author><author><name sortKey="Unl H Zarc, K R Ad" uniqKey="Unl H Zarc K">Kürşad Unlühızarcı</name></author><author><name sortKey="Tutu, Ahmet" uniqKey="Tutu A">Ahmet Tutuş</name></author><author><name sortKey="Bayram, Fahri" uniqKey="Bayram F">Fahri Bayram</name></author><author><name sortKey="Coban, Ganime" uniqKey="Coban G">Ganime Coban</name></author></titleStmt><publicationStmt><date when="2012">2012</date><idno type="doi">10.4274/Mirt.4</idno><idno type="RBID">pubmed:23487397</idno><idno type="pmid">23487397</idno><idno type="wicri:Area/Main/Corpus">000742</idno><idno type="wicri:Area/Main/Curation">000742</idno><idno type="wicri:Area/Main/Exploration">000B69</idno></publicationStmt></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The patient with a history of bone pain and muscle weakness, was thought to have oncogenic osteomalacia as a result of biochemical investigations and directed to Nuclear Medicine Department for a whole-body bone scintigraphy and 111In-octreotide scintigraphy. There was no focal pathologic tracer uptake, but generalized marked increase in skeletal uptake on bone scintigraphy. Octreotide scintigraphy showed accumulation of octreotide in the region of the left lobe of the thyroid gland in the neck. Thereafter, parathyroid scintigraphy was performed with technetium-99m labeled metroxy-isobutyl-isonitryl (99mTc-MIB) and MIBI scan demonstrated radiotracer uptake at the same location with octreotide scintigraphy. The patient underwent left inferior parathyroidectomy and histopathology confirmed a parathyroid adenoma. Somatostatin receptor positive parathyroid adenoma may show octreotide uptake. Octreotide scintigraphy may be promising and indicate a possibility of using somatostatin analogues for the medical treatment of somatostatin receptor positive Conflict of interest:None declared.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE"><PMID Version="1">23487397</PMID><DateCreated><Year>2013</Year><Month>03</Month><Day>14</Day></DateCreated><DateCompleted><Year>2013</Year><Month>03</Month><Day>17</Day></DateCompleted><DateRevised><Year>2014</Year><Month>05</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">2146-1414</ISSN><JournalIssue CitedMedium="Print"><Volume>21</Volume><Issue>2</Issue><PubDate><Year>2012</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Molecular imaging and radionuclide therapy</Title><ISOAbbreviation>Mol Imaging Radionucl Ther</ISOAbbreviation></Journal><ArticleTitle>Octreotide uptake in parathyroid adenoma.</ArticleTitle><Pagination><MedlinePgn>77-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.4274/Mirt.4</ELocationID><Abstract><AbstractText>The patient with a history of bone pain and muscle weakness, was thought to have oncogenic osteomalacia as a result of biochemical investigations and directed to Nuclear Medicine Department for a whole-body bone scintigraphy and 111In-octreotide scintigraphy. There was no focal pathologic tracer uptake, but generalized marked increase in skeletal uptake on bone scintigraphy. Octreotide scintigraphy showed accumulation of octreotide in the region of the left lobe of the thyroid gland in the neck. Thereafter, parathyroid scintigraphy was performed with technetium-99m labeled metroxy-isobutyl-isonitryl (99mTc-MIB) and MIBI scan demonstrated radiotracer uptake at the same location with octreotide scintigraphy. The patient underwent left inferior parathyroidectomy and histopathology confirmed a parathyroid adenoma. Somatostatin receptor positive parathyroid adenoma may show octreotide uptake. Octreotide scintigraphy may be promising and indicate a possibility of using somatostatin analogues for the medical treatment of somatostatin receptor positive Conflict of interest:None declared.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Karaçavuş</LastName><ForeName>Seyhan</ForeName><Initials>S</Initials><Affiliation>Bozok University School of Medicine, Nuclear Medicine Department of, Yozgat, Turkey.</Affiliation></Author><Author ValidYN="Y"><LastName>Kula</LastName><ForeName>Mustafa</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Cihan Karaca</LastName><ForeName>Züleyha</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Unlühızarcı</LastName><ForeName>Kürşad</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Tutuş</LastName><ForeName>Ahmet</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Bayram</LastName><ForeName>Fahri</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Coban</LastName><ForeName>Ganime</ForeName><Initials>G</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType>Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>08</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Turkey</Country><MedlineTA>Mol Imaging Radionucl Ther</MedlineTA><NlmUniqueID>101584839</NlmUniqueID></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Clin Endocrinol (Oxf). 2008 Nov;69(5):756-62</RefSource><PMID Version="1">18485119</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Thyroid. 2009 Apr;19(4):381-9</RefSource><PMID Version="1">19355828</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Head Neck Pathol. 2008 Dec;2(4):305-8</RefSource><PMID Version="1">20614300</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Nucl Med. 2002 Apr;27(4):304-5</RefSource><PMID Version="1">11914679</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Hum Pathol. 2003 Jan;34(1):54-64</RefSource><PMID Version="1">12605367</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>CMAJ. 1991 Aug 1;145(3):227-8</RefSource><PMID Version="1">2070313</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Surgery. 1991 Dec;110(6):1078-85</RefSource><PMID Version="1">1720902</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Endocr Rev. 1991 Nov;12(4):450-82</RefSource><PMID Version="1">1684746</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Br J Surg. 1994 Aug;81(8):1141-3</RefSource><PMID Version="1">7953342</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Surgery. 1997 Jun;121(6):606-10</RefSource><PMID Version="1">9186459</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer. 1999 Jan 1;85(1):188-98</RefSource><PMID Version="1">9921992</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AJR Am J Roentgenol. 2007 Jun;188(6):1706-15</RefSource><PMID Version="1">17515397</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2008 Feb 20;26(6):963-70</RefSource><PMID Version="1">18281671</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Endocr Relat Cancer. 2008 Sep;15(3):701-20</RefSource><PMID Version="1">18524947</PMID></CommentsCorrections></CommentsCorrectionsList><OtherID Source="NLM">PMC3590975</OtherID><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Parathyroid adenoma</Keyword><Keyword MajorTopicYN="N">indium-111-octreotide</Keyword><Keyword MajorTopicYN="N">somatostatin</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>6</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="epublish"><Year>2012</Year><Month>8</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>3</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>3</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>3</Month><Day>15</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="doi">10.4274/Mirt.4</ArticleId><ArticleId IdType="pubmed">23487397</ArticleId><ArticleId IdType="pmc">PMC3590975</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=IndiumV2/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000B69 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000B69 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= *** parameter Area/wikiCode missing ***
|area= IndiumV2
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:23487397
|texte= Octreotide uptake in parathyroid adenoma.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:23487397" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a IndiumV2
| This area was generated with Dilib version V0.5.76. |  |